BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gudmundsdottir H, Möller PH, Jonasson JG, Björnsson ES. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study. Scand J Gastroenterol 2019;54:69-75. [PMID: 30638086 DOI: 10.1080/00365521.2018.1553061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Hong L, Wang Y, Zhang T, Zhang C, Wang L, Wang L, Wang Z, Zhong J. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population. Med Sci Monit 2020;26:e926635. [PMID: 33141811 DOI: 10.12659/MSM.926635] [Reference Citation Analysis]
2 Michael M, Thursfield V, Te Marvelde L, Kong G, Hicks RJ. Incidence, prevalence, and survival trends for neuroendocrine neoplasms in Victoria, Australia, from 1982 to 2019: Based on site, grade, and region. Asia Pac J Clin Oncol 2021. [PMID: 34821050 DOI: 10.1111/ajco.13671] [Reference Citation Analysis]
3 Søreide JA, Kvaløy JT, Lea D, Sandvik OM, Al-Saiddi M, Haslerud TM, Garresori H, Karlsen LN, Gudlaugsson E, Søreide K. The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study. Cancer Rep (Hoboken) 2021;:e1462. [PMID: 34105314 DOI: 10.1002/cnr2.1462] [Reference Citation Analysis]
4 Watanabe A, Yip L, Hamilton TD, Loree JM, Stuart HC. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors. Am J Surg 2021;221:1141-9. [PMID: 33795127 DOI: 10.1016/j.amjsurg.2021.03.027] [Reference Citation Analysis]
5 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Sun S, Wang W, He C. Cardiovascular Mortality Risk among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry-Based Analysis. Oxid Med Cell Longev 2021;2021:9985814. [PMID: 34257826 DOI: 10.1155/2021/9985814] [Reference Citation Analysis]
7 Kaçmaz E, Sarasqueta AF, van Eeden S, Dreijerink KMA, Klümpen HJ, Tanis PJ, van Dijkum EJMN, Engelsman AF. Update on Incidence, Prevalence, Treatment and Survival of Patients with Small Bowel Neuroendocrine Neoplasms in the Netherlands. World J Surg 2021;45:2482-91. [PMID: 33895862 DOI: 10.1007/s00268-021-06119-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Low SK, Giannis D, Bahaie NS, Trong BLH, Moris D, Huy NT. Competing Mortality in Patients With Neuroendocrine Tumors. Am J Clin Oncol 2019;42:668-74. [PMID: 31343423 DOI: 10.1097/COC.0000000000000575] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep 2021;23:43. [PMID: 33719003 DOI: 10.1007/s11912-021-01029-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ptasnuka M, Ozolins A, Narbuts Z, Truskovs A, Sperga M, Plaudis H. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia. World J Surg 2020;44:585-93. [PMID: 31605174 DOI: 10.1007/s00268-019-05219-0] [Reference Citation Analysis]